Collectively, these results indicate that targeting CA9 cooperates with cisplatin to eliminate gefitinib-resistant cells in the heterogeneous tumor cell populations by inducing ferroptosis, as shown in Figure 6(i). Here, CA9 is linked to neoplasm.